Initial presentations and final outcomes of primary pyogenic liver abscess: a cross-sectional study

Chang-Hua Chen1,5*, Shung-Sheng Wu2, Hung-Chi Chang3 and Yu-Jun Chang4

Abstract

Background: Although pyogenic liver abscess (PPLA) fatalities are decreasing owing to early diagnosis and effective treatments, PPLA-associated complications still exist. The purpose of this study was to analyze the characteristic features of initial presentations and final outcomes of PPLA caused by different pathogens.

Methods: This retrospective study collected and analyzed information regarding initial presentations and final outcomes in patients diagnosed with PPLA at Changhua Christian Hospital from January 1 to December 31, 2010.

Results: During the study period, we analyzed the records of a total of 134 patients with documented PPLA. There were no significant causative pathogen-related differences in symptoms at initial presentation. Compared with the survivor group, patients in the mortality group were characterized by male gender (\( p < 0.001 \)), malignancy (\( p < 0.001 \)), respiratory distress (\( p = 0.007 \)), low blood pressure (\( p = 0.024 \)), jaundice (\( p < 0.001 \)), rupture of liver abscess (\( p < 0.001 \)), endophthalmitis (\( p = 0.003 \)), and multiple organ failure (\( p < 0.001 \)). No patients received liver transplantation or were diagnosed with HIV during the study period. According to univariate logistic regression analysis, gender (OR = 1.185, 95% CI: 0.284–11.130, \( p = 0.006 \)), malignancy (OR = 2.067, 95% CI: 1.174–13.130, \( p = 0.004 \)), respiratory distress (OR = 1.667, 95% CI: 1.164–14.210, \( p = 0.006 \)), low blood pressure (OR = 2.167, 95% CI: 2.104–13.150, \( p = 0.003 \)), jaundice (OR = 1.9, 95% CI: 1.234–13.140, \( p = 0.005 \)), rupture of liver abscess (OR = 5.167, 95% CI: 2.194–23.150, \( p = 0.003 \)), endophthalmitis (OR = 2.167, 95% CI: 1.234–13.140, \( p = 0.005 \)), and multiple organ failure (OR = 3.067, 95% CI: 1.184–15.150, \( p = 0.001 \)) differed significantly between the mortality and survivor groups.

Conclusion: Although the initial presentations of PPLA caused by different pathogens were similar, there were significant differences in mortality in cases involving: (1) male patients, (2) malignancy, (3) initial respiratory distress, (4) initial low blood pressure, (5) jaundice, (6) rupture of liver abscess, (7) endophthalmitis, and (8) multiple organ failure. We strongly recommend using a severity score of the disease to determine the risk of mortality for each patient with PPLA. In order to prevent complications and reduce mortality, more attention must be paid to high-risk PPLA patients.

Keywords: Primary pyogenic liver abscess, Initial presentation, Outcome complications, Mortality, Risk factors
Since the clinical symptoms of PPLA are variable, and some of the PPLA causative pathogens, such as *Klebsiella pneumoniae* (*K. pneumoniae*), are highly resistant to the most effective antibiotic therapies, it is very important to develop accurate and effective diagnosis and treatment approaches for PPLA. Early diagnosis of patients with liver abscess is one of the most challenging tasks for a physician. Over the past 3 decades, ultrasound has had an important role in the diagnosis of this disease. Even with aggressive treatment with antibiotics and drainage, however, the mortality rate of liver abscess remains high [6-8].

It is often difficult to promptly diagnose the initial stage of PPLA because ultrasound findings are typically negative or non-specific and subclinical symptoms and signs are absent. We performed a cross-sectional study of all of the confirmed cases of PPLA in central Taiwan in order to (1) elucidate the risk factors for PPLA, (2) compare the most common ultrasound findings between PPLA cases caused by different pathogens, and (3) identify the prognostic factors for mortality.

**Methods**

**Setting and population**

The population of Changhua is mostly served by the Changhua Christian Hospital System (CCHS), which has maintained comprehensive clinical records since 1867. Changhua County is located in central Taiwan, and it had a population of 140,277 in 2000. Changhua Christian Hospital (CCH), a 1,800-beds tertiary referral medical center located in northern Changhua County, is a component of CCHS. CCH has been a Joint Commission International-accredited hospital since 2009. This cross-sectional retrospective study of PPLA was conducted by reviewing the computerized medical records collected at CCH from January 1 to December 31, 2010. The study was approved by the institutional review board of Changhua Christian Hospital (CCH IRB No. 131116).

**Case findings and analysis**

Cases of PPLA at CCH were identified using the microbiological databases and medical records in the International Classification of Diseases, Ninth revision, Clinical Modifications (ICD-9-CM). We used ICD-9-CM code number 572.0 to find the cases. Each case had a medical chart that contained medical diagnoses, surgical interventions, and other key data from the medical records. The medical records of all the PPLA cases were manually reviewed by the primary investigator (C.C.H.) to confirm the diagnosis (using CCHS resources). Cases that were judged ambiguous were reviewed by the secondary investigator (S.S.W.). For example, although in some patients the abscess culture revealed *Corynebacterium urealyticum*, blood cultures grew *Staphylococcus epidermidis*, possibly because of skin contamination. Discrepancies between the abscess and blood cultures were also observed in some cases with secondary pyogenic liver abscess, such as after foreign body penetration of the alimentary tract. Only the first episode of PPLA in each person during the study period was included in statistical analyses.

PPLA was diagnosed based on clinical presentation, imaging findings of ultrasonography, abdominal computed tomography (CT) scans, and microbiological results. The treatment protocol for PPLA is described in the Additional file 1. The choice of the antimicrobial agent for the treatment was based on the results of the antibiotic susceptibility test. The following patient details were recorded: age, sex, date of admission, severity of underlying disease, comorbidity, diagnosis, clinical signs and symptoms, microbiological results, response to therapy, complications, and outcome. Only primary cases were collected, whereas those cases with distant metastasis from significant pyogenic infectious sources other than the liver were excluded. The severity of underlying disease was categorized according to the McCabe & Jackson criteria [9]. Microbiological data were collected only at the initial stage before the antibiotic therapy. All bacterial pathogens were collected, including anaerobes. If both blood and pus cultures were positive, we analyzed only the pus culture taken directly from the liver abscess. If there were recurrent PPLA episodes, only the first instance was taken into account.

Microbiological data were collected by reviewing the computerized records of the Microbiological Laboratory of CCH dated from January 1 to December 31, 2010. Blood culture analysis was performed for every case with suspected sepsis. We used a BACTEC NR-860 system (Becton Dickinson Diagnostic Instrument Systems, Cockeysville, MD, USA) to detect pathogens, Gram staining to determine morphology, and the API-20 series kit (bioMerieux Vit tek, Hazelwood, MO) for biochemical reactions. Antibiotic susceptibilities were determined using the disk diffusion method (BBL™ Sensi-Disc™, Becton Dickinson) according to the guidelines of the Clinical and Laboratory Standards Institute [10].

**Definitions**

PPLA was defined as the final diagnosis of primary pyogenic liver abscess in an adult patient (age ≥18 years) confirmed with clinical presentation, imaging findings, microbiological results, and/or pathological findings. Patients with the following characteristics were excluded: (1) age <18 years; (2) unavailable blood and pus culture data; (3) incomplete data; (4) inconsistencies among ICD-9-CM data, microbiological data, and medical records; (5) amebic liver abscess; and (6) secondary pyogenic liver abscess, such as pyogenic liver abscess secondary to foreign body penetration of the alimentary tract. Initial presentation was defined as the symptoms, signs, laboratory data
Morganella morganii, teus mirabilis whose microbiological culture revealed GNB other than Gram-negative bacilli (GNB) group comprised patients whose microbiological culture revealed GNB other than K. pneumoniae, Escherichia coli, K. terrigena, Morganella morganii, Pseudomonas aeruginosa, and Proteus mirabilis. The aerobic Gram-positive cocci (GPC) group included patients whose microbiological culture revealed GPC, including Staphylococcus aureus and viridans streptococci. The anaerobes group was composed of patients with anaerobic organisms in the microbiological culture, including Fusobacterium necrophorum, F. varium, and F. nucleatum. The mixed infection group included patients with more than 1 pathogen in the microbiological culture. Patients with polymicrobial infections were assigned to the mixed infection group. The mortality group included individuals who died within 6 weeks during the hospitalization from PPLA-related causes. The survivor group included those who did not die during the hospitalization. Abscesses were considered cryptogenic in origin when no causative lesions were apparent.

To analyze case characteristics and laboratory parameters of each group, descriptive statistics were calculated using SPSS version 10.0 for Windows (SPSS Inc., Chicago, IL, USA). Chi-square and Fisher’s exact tests were used for analysis. Results were considered significant if the p-value was <0.05.

Results
One hundred fifty PPLA cases were diagnosed from January 1 to December 31, 2010. Sixteen cases were excluded because of inadequate data, leaving a total of 134 patients with documented PPLA. The incidence of PPLA in adults served by CCH was 275.4/100,000 patient-years in 2010. The male to female ratio was 0.3 (29.1). The mean age was 59.4 years (mean ± SD: 59.4 ± 16.3; median: 62.9; range: 9–88). The mean length of hospitalization was 14.6 days (mean ± SD: 14.2 ± 7.3; median: 15; range: 1–58). Clinically, 118 of 134 (88.1%) patients had fever, and 38 (26.7%) had low blood pressure (<90/60 mmHg) upon admission for PPLA. One hundred nine (85.2%) patients had right upper quarter pain at admission. The abscesses were located at the right liver lobe in 92 (68.7%), left lobe in 21, and both lobes in 7 cases. The liver abscess size ranged from 1 to more than 5 cm in diameter. One hundred twenty-seven (94.8%) patients had a single abscess, and 7 had multiple abscesses. Ninety-five (70.9%) out of 134 patients had abscesses that resulted from infection with K. pneumoniae. There were no statistically significant differences in the initial clinical presentations among the 134 patients, and symptoms at initial clinical presentations included fever, chills, abdominal pain, anorexia, malaise, nausea, emesis, body temperature higher than 38.3°C, right upper quadrant tenderness, Murphy’s sign, hepatomegaly, disturbance of consciousness, and ascites. The initial ultrasonographic findings and the results of the initial ultrasound-guided aspiration biopsy are listed in Table 1.

Every patient received treatment according to the PPLA treatment protocol (see Additional file 1). In every case, an empirical antibiotic treatment was started at the onset of the clinical signs of infection. Antibiotic therapies were changed based on the results of antibiotic susceptibility tests. Twenty-one (15.7%) patients developed complications, including endophthalmitis, PPLA rupture, and multiple organ failure. Of 134 patients, 6 died, leading to a crude mortality rate of 4.5% (6/134). The risk factors for mortality associated with PPLA included extra-hepatic complications, PPLA rupture, and multiple organ failure. One of 6 patients did not receive drainage because of bleeding tendency and ascites.

We compared the survivor and mortality groups to analyze the risk factors of the final outcome among the 134 patients with PPLA (Table 2). When compared with the survivor group, patients with mortality were male (26.6% vs. 83.3%, p < 0.001), malignancy (28.9% vs. 66.7%, p < 0.001), respiratory distress (11.7% vs. 50%, p = 0.007), low blood pressure (29.7% vs. 33.3%, p = 0.001), jaundice (15.6% vs. 83.3%, p < 0.001), rupture of liver abscess (9% vs. 33.3%, p < 0.001), endophthalmitis (5.6% vs. 33.3%, p = 0.003), and multiple organ failure (3.1% vs. 100%, p < 0.001). In our study, no patients received liver transplantation, and none were diagnosed with HIV during the study period.

According to the results of univariate logistic regression analysis, gender (OR = 1.185, 95% CI: 0.284–11.130, p = 0.06), malignancy (OR = 2.067, 95% CI: 1.174–13.130, p = 0.004), respiratory distress (OR = 1.667, 95% CI: 1.164–14.210, p = 0.006), low blood pressure (OR = 2.167, 95% CI: 2.104–13.150, p = 0.003), jaundice (OR = 1.9, 95% CI: 1.246–3.297, p = 0.008), rupture of liver abscess (OR = 5.167, 95% CI: 2.194–23.150, p = 0.003), endophthalmitis (OR = 2.167, 95% CI: 1.234–13.140, p = 0.005), and multiple organ failure (OR = 3.067, 95% CI: 1.184–15.150, p = 0.001) differed significantly between the mortality and survivor groups.

Discussion
To the best of our knowledge, this is the first study to analyze the initial clinical presentations and initial
ultrasonographic findings in patients with PPLA caused by different pathogens. Importantly, in 6 (7.5%) of 80 patients with bacteremia, infectious foci at the initial stage were not detected during the abdominal ultrasonographic examination (Table 1), but were revealed with abdominal CT. Lin et al. showed that 38 (14.1%) of 268 PPLA patients had false-negative findings on ultrasonography at initial presentation [5]. Appropriate targeted antimicrobial treatments, combined with drainage of liver abscesses, have already increased PPLA survival rates [1,4]. Earlier diagnosis of PPLA could minimize sequelae and improve clinical outcomes [4]. Therefore, clinicians should pay special attention to bacteremic patients without obvious infectious foci. In particular, abdominal CT may be useful in patients at high risk of PPLA if initial results of abdominal ultrasonography are negative.

Although 9 of the 134 (6.7%) patients from this study did not undergo ultrasound-guided aspiration biopsy because of aspiration difficulties, their final clinical outcomes did not differ from those of the rest of the patients (Table 2). Evaluation of the final outcomes and duration of the treatment with antimicrobial agents revealed no significant differences between the patients without gas-forming and multiple abscesses (Table 1). In contrast to the results of Chou et al. [11], the current study and some previous studies [12,13] suggest that abscess multiloculation is not the single risk factor for PPLA mortality.

We compared the clinical presentations among different causative pathogens, including K. pneumonia, the main cause of liver abscesses in Taiwan with increasing infection prevalence [14]. There were no significant differences among the causative pathogens. In agreement with the previous reports from Taiwan, K. pneumoniae was the most predominant pathogen [15]. Sachdev et al. suggested that serotype K1 is an important factor of complicated endophthalmitis in K. pneumoniae-caused PPLA [16]. We did not test the serotype of K. pneumoniae because of the lack of adequate equipment. In brief, there was no significant difference in K. pneumonia-related PPLA (97.9% vs. 2.1%, p = 0.297) between the survival and mortality groups in this study. The different of our results from previous studies [4,14,15] could be related to multiple factors, including initial broad-spectrum antibiotics prescription, and fewer K1 serotype of K. pneumoniae in Changhua County, and it’s needed further experiments to elucidate these points.

With the development of appropriate antimicrobial treatments and drainage methods for liver abscesses, PPLA survival rates have increased during this century [1,4]. In our study population, the crude mortality rate was 4.5% (6/134). Overall, the crude PPLA mortality rate has varied in the recent decade, with the average value being around 5% [7,16-18]. The mortality rates varied according to the differences in the geographic origins, study designs, study arms, and patient populations [4,17]. A literature review indicated that malignancy on presentation is an important risk factor for PPLA mortality [18-20], similar to our results. In our study, the risk factors associated with PPLA mortality included gender, jaundice, rupture of liver abscess, and multiple organ failure. Some of these factors have been described previously, including jaundice [21], rupture of liver abscess [21,22], and endophthalmitis [22]. Although the differences between genders could be related to testosterone levels [23], further experiments will be need to verify this. Multiple organ failure, initial low blood pressure, and initial respiratory distress are poor prognostic factors that result from higher disease severity, contributing to the higher mortality rates in the corresponding groups. In agreement with the results of Lin et al. [24], our study revealed an association between the prolonged delay of effective antibiotics and aspiration/drainage therapies and the risk of mortality. Although in the present study the time intervals between the presentation and initiation of effective antibiotics varied within a wide range because of the non-specific and highly variable nature of PPLA presentations, we strongly recommend that an early, empirical, short-course, broad-spectrum antibiotics therapy is considered when persistent fever or unstable hemodynamics occur during the initial stages of the empirical therapy. The Lin’s report identified 6 independent risk factors predicting severe complications of K. pneumonia-related

### Table 1 Initial ultrasonographic findings and initial aspiration among 134 pyogenic liver abscess patients

|                     | Klebsiella pneumonia (n=95) | Non-Klebsiella GNB (n=31) | Aerobic GPC (n=5) | Anaerobes (n=1) | Mixed infection (n=2) | Total (n=134) | P-value |
|---------------------|----------------------------|---------------------------|------------------|----------------|----------------------|---------------|---------|
| Negative or equivocal findings of ultrasonographic examinations at first examination | 8                          | 1                         | 1                | 0              | 1                    | 11            | 1.000   |
| Difficulty at initial aspiration | 8                          | 1                         | 0                | 0              | 0                    | 9             | 0.284   |
| Gas formation       | 21                         | 6                         | 0                | 0              | 1                    | 28            | 0.591   |
| Multiple abscesses  | 2                          | 4                         | 1                | 0              | 0                    | 7             | 0.022   |
| Complications       | 5                          | 3                         | 1                | 0              | 1                    | 10            | 0.001   |
| Mortality           | 6                          | 3                         | 1                | 0              | 0                    | 11            | 0.297   |

Notes: abbreviation: GNB Gram negative bacilli, GPC Gram positive cocci.
### Table 2 Analysis of demographic data, clinical features, concomitant diseases and outcome among 134 patients with primary pyogenic liver abscess

| Demographic data                                    | Survivor | Mortality | Total | p value | Odds ratio | 95% confidence interval | P-value |
|-----------------------------------------------------|----------|-----------|-------|---------|------------|--------------------------|---------|
| N = 128 (%)                                         | N = 6 (%)| N = 134(%)|       |         |            |                          |         |
| Gender, male (%)                                    | 34 (26.6%)| 5 (83.3%)| 39 (29.1%)| <0.001 | 1.879      | 2.284–11.130             | 0.006   |
| Age, mean ± SD (years)                              | 53.6 ± 18.9| 67.5 ± 7.4| 59.4 ± 16.3| 0.705 |            |                          |         |
| Length of hospitalization, mean ± SD (days)         | 10.2 ± 8.3| 17.2 ± 6.3| 14.2 ± 7.3| 0.612 |            |                          |         |
| Underlying diseases & co-morbidity                  |          |           |       |         |            |                          |         |
| Category C of disease severity on admission a², mean ± SD | 15 (11.7%)| 2 (33.3%)| 17 (10.4%)| 0.025 |            |                          |         |
| Coexisting diseases, no. (%)                        |          |           |       |         |            |                          |         |
| Diabetes mellitus                                   | 84 (65.6%)| 2 (33.3%)| 86 (64.2%)| 0.055 |            |                          |         |
| Biliary disorders*³                                 | 44 (34.4%)| 4 (66.7%)| 48 (35.8%)| 0.055 |            |                          |         |
| Alcoholism                                           | 45 (35.2%)| 2 (33.3%)| 47 (35.1%)| 1.000 |            |                          |         |
| Liver cirrhosis                                      | 46 (35.9%)| 3 (50%)| 49 (36.6%)| 0.530 |            |                          |         |
| Malignancy*⁴                                         | 37 (28.9%)| 4 (66.7%)| 41 (30.6%)| <0.001| 2.067      | 1.174–13.130             | 0.004   |
| Uremia                                              | 49 (38.3%)| 3 (50%)| 52 (37.6%)| 0.750 |            |                          |         |
| Delay issue                                          |          |           |       |         |            |                          |         |
| Patient delay (days), mean (range)                   | 10 (1–124)| 9 (1–91)| 19 (1–124)| 0.569 |            |                          |         |
| Total delay (days), mean (range)                     | 10 (1–124)| 9 (1–91)| 19 (1–124)| 0.459 |            |                          |         |
| Symptoms and signs on admission, no. (%)             |          |           |       |         |            |                          |         |
| Fever/chills                                        | 118 (92.2%)| 4 (66.7%)| 122 (91.0%)| 0.069 |            |                          |         |
| Abdominal pain                                       | 117 (91.4%)| 5 (83.3%)| 122 (91.0%)| 0.256 |            |                          |         |
| Anorexia                                             | 12 (9.4%)| 2 (33.3%)| 14 (10.5%)| 0.056 |            |                          |         |
| Malaise                                              | 115 (89.9%)| 5 (83.3%)| 120 (89.6%)| 0.322 |            |                          |         |
| Nausea/emesis                                        | 114 (89.1%)| 4 (66.7%)| 118 (12.7%)| 0.057 |            |                          |         |
| Respiratory distress*⁵                               | 15 (11.7%)| 3 (50%)| 18 (13.4%)| 0.007 | 1.667      | 1.164–14.210             | 0.006   |
| Signs on admission, no. (%)                          |          |           |       |         |            |                          |         |
| Body temperature > 38.3°C                            | 111 (86.7%)| 6 (100%)| 117 (87.3%)| 0.358 |            |                          |         |
| Blood pressure < 90/60 mmHg                          | 38 (29.7%)| 2 (33.3%)| 40 (29.8%)| 0.001 | 2.167      | 2.104–13.150             | 0.003   |
| Right upper quadrant tenderness                      | 109 (85.2%)| 3 (50%)| 112 (83.6%)| 0.701 |            |                          |         |
| Jaundice                                             | 20 (15.6%)| 5 (83.3%)| 25 (18.7%)| <0.001| 1.900      | 1.246–3.297             | 0.008   |
| Murphy’s sign*⁶                                       | 21 (16.4%)| 1 (16.7%)| 22 (16.4%)| 0.869 |            |                          |         |
| Hepatomegaly                                         | 22 (17.2%)| 0 (0%)| 22 (16.4%)| 0.125 |            |                          |         |
| Disturbance of consciousness                         | 23 (17.8%)| 1 (16.7%)| 24 (17.9%)| 0.980 |            |                          |         |
| Ascites                                              | 24 (18.8%)| 1 (16.7%)| 25 (18.7%)| 1.000 |            |                          |         |
| Source of infection, no. (%)                         |          |           |       |         |            |                          |         |
| Biliary origin*⁷                                      | 32 (25%)| 4 (66.7%)| 36 (26.9%)| 0.069 |            |                          |         |
| Cryptogenic origin                                   | 33 (25.8%)| 1 (16.7%)| 34 (25.4%)| 0.729 |            |                          |         |
| Sonographic findings at first examination, no (%)    |          |           |       |         |            |                          |         |
| Negative findings and equivocal                      | 5 (83.3%)| 1 (16.7%)| 6 (45%)| 0.077 |            |                          |         |
| Single abscesses (77%)                               | 101 (98.1%)| 2 (1.9%)| 103 (77%)| 0.063 |            |                          |         |
| Right lobe (72.3%)                                   | 95 (97.9%)| 2 (2.1%)| 97 (72.3%)| 0.071 |            |                          |         |
| Multiple abscesses (23%)                             | 30 (96.8%)| 1 (3.2%)| 31 (23%)| 1.000 |            |                          |         |
liver abscess: thrombocytopenia (<100,000/mm3), alkaline phosphatase > 300 U/L, gas formation in the abscess, APACHE III score > 40, use of cefazolin (instead of extended-spectrum cephalosporin), and delayed drainage [24,25].

Our study has several strengths. Most importantly, it represents an reliable reference for evaluating the initial clinical features of PPLA, providing valuable epidemiological information regarding the confirmed PPLA cases in central Taiwan. In addition, the prognostic factors, including the initial presentations, were analyzed. The limitations of this study include the retrospective cross-sectional design. The true prevalence of PPLA may be under-estimated because we collected only the cases with definitive diagnosis and positive microbiological findings in order to reduce potential confounding factors. Moreover, every case of polymicrobial liver abscess was considered a single case, with the predominant pathogen determined based on the results of microbiological evaluation. Similarly, only the results of liver abscess pus culture were taken into account if both blood and pus cultures were positive. Furthermore, since recurrent PPLA was counted as one case, the true incidence of PPLA is likely to be under-estimated. Finally, we did not calculate the time interval between definitive diagnosis and the initiation of effective antibiotic treatment.

**Conclusions**

Because of early diagnosis and availability of more effective treatments, PPLA mortality is currently decreasing. Nevertheless, complications and mortality were still present in the current study. Although the initial presentations of PPLA were not significantly different among the groups with different causative pathogens, the disease was treated successfully in the majority of the patients. The mortality of the patients with PPLA was associated with: (1) male gender, (2) presence of malignancy, (3) initial respiratory distress, (4) initial low blood pressure, (5) jaundice, (6) rupture of liver abscess, (7) endophthalmitis, and (8) multiple organ failure. We strongly recommend using a disease severity score to determine the risk of mortality for each patient with PPLA. In order to prevent complications and reduce mortality, more attention must be paid to high-risk PPLA patients.

**Table 2 Analysis of demographic data, clinical features, concomitant diseases and outcome among 134 patients with primary pyogenic liver abscess (Continued)**

|                          | Group A (n=57) | Group B (n=77) | p-value |
|--------------------------|----------------|----------------|---------|
| Gas formation            | 27 (96.4%)     | 1 (3.6%)       | 1.000   |
| Difficulty at initial aspiration | 8 (88.9%)     | 1 (11.1%)      | 0.161   |
| Microbiology             |                | 0.028          |
| Klebsiella pneumonia     | 93 (97.9%)     | 2 (2.1%)       | 0.708   |
| Non- Klebsiella GNB      | 28 (90.3%)     | 3 (9.7%)       | 0.311   |
| Aerobic GPC              | 4 (80%)        | 1 (20%)        | 0.759   |
| Anaerobes                | 1 (100%)       | 0              | 0.410   |
| Mixed infection          | 2 (100%)       | 0              | 0.141   |

**Treatment**

|                          | Group A (n=57) | Group B (n=77) | p-value |
|--------------------------|----------------|----------------|---------|
| Doctor delay of effective antibiotics therapy (days), mean (range) | 8 (0–33)       | 4 (0–37)       | 0.101   |
| Prolonged doctor delay of effective antibiotics therapy (>8 days) | 78 (61.5%)     | 2 (33.3%)      | 0.518   |
| Delay of aspiration/drainage (days), mean (range) | 9 (0–33)       | 7 (0–27)       | 0.201   |
| Prolonged delay of aspiration/drainage therapy (>9 days) | 78 (61.5%)     | 1 (16.7%)      | 0.008   |

**Complications, no. (%)**

|                          | Group A (n=57) | Group B (n=77) | p-value |
|--------------------------|----------------|----------------|---------|
| Rupture of liver abscess | 0 (0%)         | 2 (33.3%)      | <0.001  |
| Endophthalmitis, related to PPLA | 7 (5.6%)     | 2 (33.3%)      | 0.003   |
| Multiple organ failure, related to PPLA | 4 (3.1%)     | 6 (100%)       | <0.001  |

P-value by Chi-square test or Fisher’s exact test when appropriate.

Abbreviation: GNB Gram negative bacilli, GPC Gram positive cocci.

Notes: 1) Standard deviation, 2) Disease severity was categorized according to McCabe & Jackson criteria, and Category C meant the rapid fatal group; 3) Biliary disorders including biliary stone diseases (cholelithiasis, cholecdocholithiasis, or hepatolithiasis) and prior hepatobiliary surgery; 4) Malignancy including lung cancer, pancreatic cancer, breast cancer, esophagus cancer, stomach cancer, colon cancer, lymphoma, prostate cancer, hematological malignancy, oral cancer, solid tumor and large intestines. Non-digestive system cancer; 5) Respiratory distress including shortness of breath, dyspnea, chest distress, hypoxemia (saturaion of oxygen is less than 95%); 6) Murphy’s sign: deep inspiration or cough during subcostal palpation of RUQ producing increased pain and inspiratory arrest; 7) Biliary origin of liver abscess including suppurative cholangitis and acute cholecystitis.
Ethical approval
The study was approved by the institutional review board of Changhua Christian Hospital (CCH IRB No. 131116).

Additional file

**Additional file 1: Treatment protocol for pyogenic liver abscesses.**

**Abbreviations**

CCH: Changhua Christian Hospital; CCHS: Changhua Christian Hospital System; CT: Computed tomography; GNB: Gram-negative bacilli; GPC: Gram-positive cocci; PPLA: Primary pyogenic liver abscess.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

C-HC, S-SW, H-CC performed the majority of clinical services. C-HC coordinated this study and wrote the manuscript. Y-IC handled the statistical analysis. All authors read and approved the final manuscript.

**Acknowledgements**

All authors thank the assistant of the Clinical Microbiology Laboratory of Changhua Christian Hospital. This research project would not have been possible without the support of many people. The author wishes to express her gratitude to staffs of Division of Infectious Diseases and Division of Gastroenterology of Changhua Christian Hospital who were abundantly helpful and offered patient care, invaluable assistance, and support.

**Authors detail**

1. Division of Infectious Diseases, Department of Internal Medicine, Changhua Christian Hospital, 135 Nanxiao St., Changhua City, Changhua County 500, Taiwan. 2. Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, 135 Nanxiao St., Changhua City, Changhua County 500, Taiwan. 3. Department of Surgery, Changhua Christian Hospital, 135 Nanxiao St., Changhua City, Changhua County 500, Taiwan. 4. Department of Nursing, College of Medicine & Nursing, Hung Kuo University, No. 1018, Sec. 6, Taiwan Boulevard, Shalu District, Taichung 43302, Taiwan.

Received: 9 July 2014 Accepted: 18 July 2014 Published: 28 July 2014

**References**

1. Cheng HP, Chang FY, Fung CP, Su JK. Klebsiella pneumoniae liver abscess in Taiwan is not caused by a clonal spread strain. J Microbiol Immun Infect 2002, 35:85–88.
2. Hope WW, Wrochides DV, Newcomb WL, Mayo-Smith WW, Iannitti DA. Optimal treatment of hepatic abscess. Am Surg 2008, 74:178–182.
3. Gorwenka H, Bacher H, Werkgartner G, El-Shabrawi A, Kornprat P, Bernhardt GA, Mischinger HJ. Treatment of patients with pyogenic liver abscesses. Chemotherapy 2005, 51:366–369.
4. Su JW, Yeh KM, Lin JC, Fung CP, Chang FY. Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet Infect Dis 2012, 12:881–887.
5. Lin AC, Yeh DY, Hsu YH, Wu CC, Chang H, Jang TN, Huang CH. Diagnosis of pyogenic liver abscess by abdominal ultrasonography in the emergency department. Emerg Med J 2009, 26:273–275.
6. Seeto RK, Rockey D. Pyogenic liver abscess: changes in etiology, management and outcome. Medicine 1996, 75:99–113.
7. Yang CC, Chen CY, Lin XZ, Chang TT, Shin JS, Lin CY. Pyogenic liver abscess in Taiwan: emphasis on gas-forming liver abscess in diabetics. J Formos Med Assoc 1993, 92:1011–1015.
8. Mischinger HJ, Hauser H, Rabi H, Quehenberger F, Werkgartner G, Rubin R, Deu E. Pyogenic liver abscess: studies of therapy and analysis of risk factors. World J Surg 1994, 18:852–858.
9. McCabe W, Jackson CG. Gram-negative bacteremia: I. etiology and ecology. Arch Intern Med 1962, 36:1020–1027.
10. Clinical and Laboratory Standards Institute (CLSI): Methods for dilution antimicrobial susceptibility tests for bacteria that grow anaerobically—seventeenth edition: document M100-S17.
11. Chou FF, Sheen-Chen SM, Chen YS, Chen WC. Single and multiple pyogenic liver abscesses: clinical course, etiology, and results of treatment. World J Surg 1997, 21:384–389.
12. Tan YM, Chuang YC, Chow PK, Cheng HC, Woe LL, Sze KC. An appraisal of surgical and percutaneous drainage for pyogenic liver abscesses larger than 5 cm. Ann Surg 2005, 241:485–490.
13. Pang F, Fung T, Sarna J, Hugh T, Smith R. Pyogenic liver abscess: an audit of 10 years’ experience. World J Gastroenterol 2011, 17:1622–1630.
14. Chang FY, Chou MY. Comparison of pyogenic liver abscesses caused by Klebsiella pneumoniae and non-K pneumoniae pathogens. J Formos Med Assoc 1995, 94:232–237.
15. Fung CP, Lin YT, Lin JC, Yeh KM, Chang FY, Chuang HC, Wu HS, Tseng CP, Su JK. Klebsiella pneumoniae liver abscesses in gastrointestinal tract and pyogenic liver abscesses. Emerg Infect Dis 2012, 18:1322–1325.
16. Sachdev DD, Yin MT, Horowitz JD, Mukamal JS, Lee SE, Ratner AJ. Klebsiella pneumoniae K1 Liver abscess and septic endophthalmitis in a U.S. resident. J Clin Microbiol 2013, 51:1049–1051.
17. McDonald MI, Corey GR, Gallis HA, Durack DT. Single and multiple pyogenic liver abscesses. Natural history, diagnosis and treatment, with emphasis on percutaneous drainage. Medicine (Baltimore) 1984, 63:291–302.
18. Tsai FC, Huang YT, Chang CY, Wang JT. Pyogenic liver abscess as endemic disease. Taiwan. Emerg Infect Dis 2008, 14:1592–1600.
19. Tachopoulou OA, Vogt DP, Henderson JM, Baker M, Keys TF. Hepatic abscess after liver transplantation: 1990–2000. Transplantation 2003, 75:79–83.
20. McDonald MI, Corey GR, Gallis HA, Durack DT. Single and multiple pyogenic liver abscesses. Natural history, diagnosis and treatment, with emphasis on percutaneous drainage. Medicine (Baltimore) 1984, 63:291–302.
21. Tschoppoulis OA, Vogt DP, Henderson JM, Baker M, Keys TF. Hepatic abscess after liver transplantation: 1990–2000. Transplantation 2003, 75:79–83.
22. Karatassas A, Williams JA. Review of pyogenic liver abscess at the Royal Adelaide Hospital 1980–1987. Aust N Z J Surg 1990, 60:893–897.
23. Lotter H, Heik E, Benin H, Jacobs T, Pfehn C, Adamski J, Gonzalez-Roldan N, Holst O, Tannich E. Testosteron increases susceptibility to amebic liver abscess in mice and mediates inhibition of IFNγ secretion in natural killer T cells. PLoS One 2013, 8:e55694.
24. Lin JC, Chang FY. Pyogenic liver abscess associated with septic pulmonary embolism. J Chin Med Assoc 2008, 71:603–604.
25. Yeh KM, Kurok A, Su JK, Koh YL, Fung CP, Lin JC, Chen TL, Chang FY, Koh TH. Capsular serotype K1 or K2, rather than maga and rmpA, is a major virulence determinant for Klebsiella pneumoniae liver abscess in Singapore and Taiwan. J Clin Microbiol 2007, 45:466–471.